PER® Precision Medicine Symposium: An Illustrated Tumor Board | Conference

Genomic Testing and ctDNA Add to Personalized Treatment Approach in Metastatic CRC

October 29th 2022

Benjamin Adam Weinberg, MD, discussed the expanding role of circulating tumor DNA in CRC and the various testing methods, the utilization of liquid biopsies, and the need for up-front genetic testing to identify molecular alterations.

Dr. Xu on Future Developments in Kidney Cancer

October 17th 2022

Wenxin Xu, MD, discusses future considerations for the treatment of patients with kidney cancer.

Dr. Goy on Discrepancies in Clinical Trial vs Real-World MCL Treatment

October 17th 2022

Andre H. Goy, MD, discusses clinical trial vs real-world treatments in patients with mantle cell lymphoma.

Treatments for MCL Continue to Progress

October 14th 2022

As research and treatment options for patients with mantle cell lymphoma continue to expand, the development of risk-adapted therapies for the 3 primary subtypes—blastoid, smoldering, and classic broad-spectrum—represents a crucial next step in the field.

Increasingly Sensitive Genetic Testing Advances GI Cancer Diagnosis and Management

October 8th 2022

John Lindsay Marshall, MD, discusses past, present, and future developments in molecular testing, as well as the unique offerings of tissue and blood tests and the ways in which these precise approaches will ultimately make cancer diagnosis and treatment more efficient and effective.

Dr. Cristofanilli on Optimal Targeted Therapies in Metastatic HR-Positive Breast Cancer

October 5th 2022

Massimo Cristofanilli, MD, discusses the variety of targeted therapies available in metastatic hormone receptor–positive breast cancer.

Dr. Marshall on Genetic Testing in Gastrointestinal Cancer

October 5th 2022

John L. Marshall, MD, discusses the evolution of genetic testing in gastrointestinal cancer.

Tailoring Therapy for Breast Cancer in 2021: Examining and Applying Clinical Lessons

September 21st 2021

Personalized medicine has come to the forefront of breast cancer management, with genomic tools being utilized to avoid unnecessary chemotherapy in those with early-stage disease, PARP and PI3K inhibitors improving outcomes for those who harbor select mutations, and the emergence of highly active targeted agents shaking up the HER2-positive paradigm.

Dr. Goy on the Importance of Refined Decision Making With Precision Medicine

September 20th 2021

Andre H. Goy, MD, discusses the importance of refined decision making with precision medicine.

Dr. Marshall on the Importance of Molecular Profiling When Utilizing Precision Medicine

September 20th 2021

John L. Marshall, MD, discusses the importance of molecular profiling when utilizing precision medicine.

Dr. Levy on Overcoming Osimertinib Resistance in EGFR-Mutant NSCLC

September 20th 2021

Benjamin P. Levy, MD, discusses potential strategies to overcome resistance to osimertinib in EGFR-mutant non–small cell lung cancer.

Goy Taps Into the True Potential of Precision Medicine in Oncology

September 18th 2021

Current approaches to precision medicine in oncology have been fruitful, but require better integration and utilization of available resources to inform sustainable and effective drug development and clinical care, according to Andre Goy, MD.

Novel Immunotherapy Options Prompt Paradigm Shift in NSCLC Treatment

September 18th 2021

A shift in the NSCLC treatment paradigm came in the form of immunotherapy, which has since seen significant progress—mostly in the past decade.

Dr. Petrylak on Pivotal PARP Inhibitor Trials in mCRPC With DNA Repair Mutations

September 28th 2020

Daniel P. Petrylak, MD, discusses the pivotal trials that have led to the regulatory approvals of the PARP inhibitors olaparib and rucaparib in patients with metastatic castration-resistant prostate cancer and DNA repair mutations.

Dr. Levy on the Role of Dabrafenib/Trametinib in BRAF V600E-Mutant NSCLC

September 28th 2020

Benjamin P. Levy, MD, discusses the role of the combination of dabrafenib and trametinib in BRAF V600E-mutant non–small cell lung cancer.

Precision Medicine Picks up Pace Across Oncology

September 28th 2020

Andre Goy, MD, MS, discusses how matching the right treatment with the right patient resides at the heart of precision medicine, but with continued interest in pursuing the molecular milieu of cancers, precision medicine has the potential to better inform pre- and post-cancer interventions as well.

Precision Medicine Challenges Deepen in DLBCL As Subtypes Emerge

September 28th 2020

Despite efforts to advance the precision oncology portfolio for patients with diffuse large B-cell lymphoma by categorizing subtypes of the molecularly heterogenous disease, developing treatment routes for these alternate forms presents an uphill battle.

Leveraging Immunotherapy and Targeted Therapy for Cure in Lung Cancer

September 26th 2020

Efforts to leverage targeted therapy and immunotherapy, which have been approved modalities in advanced non–small cell lung cancer, are leading to improved survival in patients with advanced and earlier-stage disease.

Dr. Goy on Updates in Precision Medicine in Oncology

September 26th 2020

Andre Goy, MD, MS, discusses updates in precision medicine.

Vokes Voices How to Use Genomics to Predict Response to Checkpoint Inhibitors in Cancer

September 26th 2020

Natalie I. U. Vokes, MD, discusses the rise of predictive genomic biomarkers in oncology.